Previous 10 | Next 10 |
2024-05-15 19:43:05 ET Celcuity Inc. (CELC) Q1 2024 Earnings Conference Call May 15, 2024, 4:30 PM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief ...
2024-05-15 16:06:04 ET More on Celcuity Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript Stifel starts Celcuity at buy, sees gedatolisib as potential blockbuster Seeking Alpha’s Quant Rating on Celcuity Historical earnings data for Celcuity ...
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024 First patient dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration r...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, M...
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $24.00 for CELC on 2024-03-28 07:08:00. The adjusted price target was set to $24.00. At the time of the announcement, CELC was trading at $18.16. CELC currently trades -4.12% versus its 52 week high of...
2024-03-27 18:40:09 ET Celcuity Inc. (CELC) Q4 2023 Earnings Conference Call March 27, 2024 4:30 p.m. ET Company Participants Maria Yonkoski - ICR Westwicke Brian Sullivan - Chief Executive Officer and Co-Founder Vicky Hahne - Chief Financial Officer Igor Gor...
2024-03-27 16:28:23 ET More on Celcuity Stifel starts Celcuity at buy, sees gedatolisib as potential blockbuster Seeking Alpha’s Quant Rating on Celcuity Historical earnings data for Celcuity Financial information for Celcuity Read the full a...
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mT...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...